74 3.1. Conclusion clinique et extrapolation des résultats, p.74 ,
5%) ont bénéficié d'une prise en charge chirurgicale Quatre (66,6%) des IOA natives ont bénéficié d'un lavage, 91%) ont été opérées, par simple lavage dans 15 cas (48.3%), ou par changement en un (n=11, 35.4%) ou deux (n=5, 16%) temps. 4. Description de l'antibiothérapie, p.31 ,
5%) ont bénéficié d'un traitement par glycopeptides bien que la souche soit méti-S, du fait d'allergie ou d'effet secondaire aux pénicillines M pour deux cas, de la survenue d'une infection intercurrente dans un cas, d'une infection polymicrobienne dans trois cas ,
Pour les autres, le délai médian d'introduction de la téicoplanine était de 23 jours (IQR Les antibiotiques les plus utilisés avant la téicoplanine étaient les pénicillines M dans 10 cas (25%), les fluoroquinolones dans 10 cas (25%) et la vancomycine dans 9 cas (22.5%) La durée médiane du traitement par téicoplanine était de 45.5 jours (IQR, 29.2-78.7), pour une durée médiane de traitement antibiotique total de 124 jours (IQR, Le traitement par téicoplanine a été interrompu de façon programmée dans 19 cas (47.5%), et écourté chez 8 patients (20%) pour les raisons suivantes : 3 décès, 1 réaction inflammatoire, pp.6-535 ,
Bacterial epidemiology of osteoarticular infections in a referent center: 10-year study, Orthopaedics & Traumatology: Surgery & Research, vol.99, issue.6, pp.653-661, 2013. ,
DOI : 10.1016/j.otsr.2013.02.011
Diagnosis and treatment of implant-associated septic arthritis and osteomyelitis, Current Infectious Disease Reports, vol.32, issue.5, pp.394-403, 2008. ,
DOI : 10.1007/s11908-008-0064-1
Prothèse de hanche ou de genou : diagnostic et prise en charge de l'infection dans le mois suivant l'implantation ,
Outcome of Acute Prosthetic Joint Infections Due to Gram-Negative Bacilli Treated with Open Debridement and Retention of the Prosthesis, Antimicrobial Agents and Chemotherapy, vol.53, issue.11, pp.4772-4779, 2009. ,
DOI : 10.1128/AAC.00188-09
Optimizing combination rifampin therapy for staphylococcal osteoarticular infections, Joint Bone Spine, vol.80, issue.1, 2013. ,
DOI : 10.1016/j.jbspin.2012.09.008
Systematic review and meta-analysis of antibiotic therapy for bone and joint infections, The Lancet Infectious Diseases, vol.1, issue.3, pp.175-88, 2001. ,
DOI : 10.1016/S1473-3099(01)00094-9
Current management of prosthetic joint infections in adults: results of an Emerging Infections Network survey, International Journal of Antimicrobial Agents, vol.41, issue.3, pp.272-279, 2013. ,
DOI : 10.1016/j.ijantimicag.2012.10.023
Evaluation scientifique de Targocid et noms associés [Internet]. European Medicines Agency Available from, 2013. ,
Pharmacologie des antibiotiques en reanimation [Internet]. Société Française d'Anésthésie Réanimation Available from, 2013. ,
In vitro studies of the pharmacodynamics of teicoplanin against Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium, Clinical Microbiology and Infection, vol.9, issue.9, 2003. ,
DOI : 10.1046/j.1469-0691.2003.00692.x
In-vitro comparison of the postantibiotic effect of vancomycin and teicoplanin, Journal of Antimicrobial Chemotherapy, vol.26, issue.2, 1990. ,
DOI : 10.1093/jac/26.2.203
Clinical Pharmacokinetics of Teicoplanin, Clinical Pharmacokinetics, vol.44, issue.3, 2000. ,
DOI : 10.2165/00003088-200039030-00001
Efficacy of Teicoplanin and Autoradiographic Diffusion Pattern of [14C]Teicoplanin in Experimental Staphylococcus aureus Infection of Joint Prostheses, Antimicrob Agents Chemother, vol.42, issue.11, pp.2830-2835, 1998. ,
Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis, International Journal of Antimicrobial Agents, vol.45, issue.6, pp.647-51 ,
DOI : 10.1016/j.ijantimicag.2015.01.015
Changes in the pharmacokinetics of teicoplanin in patients with hyperglycaemic hypoalbuminaemia: Impact of albumin glycosylation on the binding of teicoplanin to albumin, International Journal of Antimicrobial Agents, vol.46, issue.2, 2015. ,
DOI : 10.1016/j.ijantimicag.2015.03.010
Teicoplanin as an Effective Alternative to Vancomycin for Treatment of MRSA Infection in Chinese Population: A Meta-analysis of Randomized Controlled Trials, PLoS ONE, vol.53, issue.11, p.79782, 2013. ,
DOI : 10.1371/journal.pone.0079782.s001
High Prevalence of Teicoplanin Resistance among Staphylococcus epidermidis Strains in a 5-Year Retrospective Study, Journal of Clinical Microbiology, vol.44, issue.5, pp.1922-1925, 2006. ,
DOI : 10.1128/JCM.44.5.1922-1923.2006
The VISA/GISA problem: therapeutic implications, Clinical Microbiology and Infection, vol.7, issue.4, pp.8-15, 2001. ,
DOI : 10.1046/j.1469-0691.2001.00054.x
Comparative safety of teicoplanin and vancomycin, International Journal of Antimicrobial Agents, vol.10, issue.2, pp.143-52, 1998. ,
DOI : 10.1016/S0924-8579(98)00025-9
Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: A retrospective chart review, Clinical Therapeutics, vol.31, issue.9, pp.1977-86, 2009. ,
DOI : 10.1016/j.clinthera.2009.09.010
The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin, International Journal of Antimicrobial Agents, vol.27, issue.4, pp.344-50, 2006. ,
DOI : 10.1016/j.ijantimicag.2005.11.012
Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study, International Journal of Antimicrobial Agents, vol.43, issue.5, pp.423-453, 2014. ,
DOI : 10.1016/j.ijantimicag.2014.01.023
Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome, Journal of Infection and Chemotherapy, vol.2, issue.4, pp.197-208, 1996. ,
DOI : 10.1007/BF02355116
Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome, Journal of Antimicrobial Chemotherapy, vol.45, issue.6, pp.835-876, 2000. ,
DOI : 10.1093/jac/45.6.835
Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose, Journal of Antimicrobial Chemotherapy, vol.51, issue.4, pp.971-976, 2003. ,
DOI : 10.1093/jac/dkg147
Treatment of bone, joint, and vascular-access-associated grampositive bacterial infections with teicoplanin, Antimicrob Agents Chemother, 1990. ,
Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis, International Journal of Antimicrobial Agents, vol.32, issue.5, pp.455-463, 2008. ,
DOI : 10.1016/j.ijantimicag.2008.05.012
Teicoplanin levels in bone and joint infections: Are standard doses subtherapeutic?, Journal of Infection, vol.55, issue.5, pp.408-421, 2007. ,
DOI : 10.1016/j.jinf.2007.07.012
Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level, Journal of Infection and Chemotherapy, vol.12, issue.4, pp.185-194, 2006. ,
DOI : 10.1007/s10156-006-0446-Y
Evaluation of teicoplanin dosing designs to achieve a new target trough concentration, Journal of Infection and Chemotherapy, vol.18, issue.3, pp.296-302 ,
DOI : 10.1007/s10156-011-0325-z
Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections, Journal of Infection and Chemotherapy, vol.16, issue.3, pp.193-202, 2010. ,
DOI : 10.1007/s10156-010-0038-8
Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrugresistant gram-positive infections, Basic Clin Pharmacol Toxicol, 2012. ,
Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation, International Journal of Antimicrobial Agents, vol.40, issue.4, pp.344-352, 2012. ,
DOI : 10.1016/j.ijantimicag.2012.05.025
Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections, Int. Journal of Clinical Pharmacology and Therapeutics, vol.53, issue.05, pp.356-62 ,
DOI : 10.5414/CP202247
Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity, International Journal of Antimicrobial Agents, vol.46, issue.4, pp.406-418, 2015. ,
DOI : 10.1016/j.ijantimicag.2015.05.019
Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease, British Journal of Clinical Pharmacology, vol.7, issue.5, pp.1197-207, 2015. ,
DOI : 10.1111/bcp.12710
Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics, International Journal of Antimicrobial Agents, vol.35, issue.5, pp.507-517, 2010. ,
DOI : 10.1016/j.ijantimicag.2009.12.018
An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication, Journal of Infection and Chemotherapy, vol.17, issue.2, pp.297-300, 2011. ,
DOI : 10.1007/s10156-010-0105-1
Increased teicoplanin doses are associated with improved serum levels but not drug toxicity, Journal of Infection, vol.68, issue.1, pp.43-52 ,
DOI : 10.1016/j.jinf.2013.08.018
Statistical analysis of the adverse effects of glycopeptide antibiotics, based on pharmacokinetics and toxicokinetics (PK/TK), Journal of Infection and Chemotherapy, vol.12, issue.3, 2006. ,
DOI : 10.1007/s10156-006-0437-Z
Dosage recommendations for teicoplanin, Journal of Antimicrobial Chemotherapy, vol.32, issue.6, pp.792-798, 1993. ,
DOI : 10.1093/jac/32.6.792
Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections, Journal of Infection and Chemotherapy, vol.21, issue.6, pp.449-55 ,
DOI : 10.1016/j.jiac.2015.02.002
Conseils pratiques. La voie sous-cutanée. Une alternative utile en soins palliatifs. Can Fam Physician, Feb, vol.47, pp.266-273, 2001. ,
Administration de médicaments par voie sous cutanée [Internet] Available from: http://pharmacie.hug-ge, 2015. ,
Subcutaneous Fluid Administration in Elderly Subjects: Validation of an Under-Used Technique, Journal of the American Geriatrics Society, vol.31, issue.6, pp.6-9, 1991. ,
DOI : 10.1111/j.1532-5415.1991.tb05898.x
Intravascular Catheter-Related Bloodstream Infection. The Neurohospitalist, pp.144-51, 2013. ,
Catheter-Related Bloodstream Infections (CR-BSI) in Geriatric Patients in Intensive Care Units, Critical Care Nursing Quarterly, vol.38, issue.3, p.2015 ,
DOI : 10.1097/CNQ.0000000000000076
Hypodermoclysis: benefits and indications in geriatrics]. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne, pp.643-50, 2005. ,
Antibiotiques par voie sous-cutan??e chez la personne ??g??e, Presse Médicale, 2009. ,
DOI : 10.1016/j.lpm.2008.07.018
Subcutaneously administered antibiotics: a national survey of current practice from the French Infectious Diseases (SPILF) and Geriatric Medicine (SFGG) society networks, Clinical Microbiology and Infection, vol.21, issue.4, 2015. ,
DOI : 10.1016/j.cmi.2014.11.017
Etude prospective de la tolérance des antibiotiques administrés par voie sous-cutanée [Internet] Available from: https, 2015. ,
Antibiothérapie par voie sous-cutanée chez le patient âgé, Rev Médicale Suisse, issue.446, pp.1924-1933, 2014. ,
Etude pharmacoclinique comparative de la ceftriaxone par voie sous-cutanée et intraveineuse chez la personne âgée, Rev Gériatrie, vol.25, issue.5, pp.337-384, 2000. ,
Subcutaneous and intravenous ceftriaxone administration in patients more than 75??years of age, M??decine et Maladies Infectieuses, vol.44, issue.6 ,
DOI : 10.1016/j.medmal.2014.03.007
Subcutaneous Administration of Cefepime, Journal of Pain and Symptom Management, vol.30, issue.2, 2005. ,
DOI : 10.1016/j.jpainsymman.2005.03.007
Ertapenem administered intravenously or subcutaneously for urinary tract infections caused by ESBL producing enterobacteriacea, Médecine Mal Infect, 2012. ,
Single-dose pharmacokinetics of ampicillin and tobramycin administered by hypodermoclysis in young and older healthy volunteers, British Journal of Clinical Pharmacology, vol.42, issue.3, pp.325-356, 1996. ,
DOI : 10.1046/j.1365-2125.1996.03967.x
Subcutaneous administration of drugs in the elderly: survey of practice and systematic literature review, Palliative Medicine, vol.12, issue.2, pp.208-227, 2005. ,
DOI : 10.1191/0269216304pm1006oa
pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis Off Publ Infect Dis Soc Am, pp.1-10, 1998. ,
Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors, Intensive Care Medicine, vol.29, issue.9, pp.1528-1562, 2003. ,
DOI : 10.1007/s00134-003-1859-z
Subcutaneous teicoplanin for children with infectious endocarditis]. Arch Pédiatrie Organe Off Sociéte Fr Pédiatrie, pp.775-783, 2013. ,
Early onset prosthetic hip and knee joint infection: treatment and outcomes in Victoria, Australia, Journal of Hospital Infection, vol.82, issue.4, 2012. ,
DOI : 10.1016/j.jhin.2012.09.005
Appropriate drug prescribing in the elderly]. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne, pp.582-90, 2004. ,
Clinical pharmacology and aging]. Presse Médicale Paris Fr 1983, Feb, vol.42, issue.2, pp.171-80, 2013. ,
Evaluation of Charlson's comorbidity index in elderly living in nursing homes, Journal of Clinical Epidemiology, vol.55, issue.11, 2002. ,
DOI : 10.1016/S0895-4356(02)00485-7
Inter-individual and intraindividual pharmacokinetic variability during teicoplanin therapy in geriatric patients ,
Pharmacocinétique de la teicoplanine chez le sujet Agé : construction d'un modèle pour le suivi thérapeutique, J Pharm Clin, vol.27, issue.3, pp.189-94, 2008. ,
Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis Off Publ Infect Dis Soc Am, pp.1651-72, 2004. ,
Outpatient Parenteral Antibiotic Therapy for Bone and Joint Infections: An Italian Multicenter Study, Journal of Chemotherapy, vol.15, issue.117, pp.417-439, 2007. ,
DOI : 10.2165/00019053-200321060-00004
A cost analysis of Outpatient Parenteral Antibiotic Therapy (OPAT): an Asian perspective, International Journal of Antimicrobial Agents, vol.33, issue.1, 2009. ,
DOI : 10.1016/j.ijantimicag.2008.07.016
Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years, Journal of Antimicrobial Chemotherapy, vol.60, issue.2, pp.356-62, 2007. ,
DOI : 10.1093/jac/dkm210
Outpatient parenteral antibiotic therapy: Principles and practice, European Journal of Internal Medicine, vol.24, issue.7 ,
DOI : 10.1016/j.ejim.2013.03.014
Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: survey of infection specialists' experience and views, Clinical Microbiology and Infection, vol.6, issue.7, pp.387-90, 2000. ,
DOI : 10.1046/j.1469-0691.2000.00112.x
Quality-of-Life Assessment in an Outpatient Parenteral Antibiotic Program, Annals of Pharmacotherapy, vol.12, issue.12, pp.1851-1856, 2002. ,
DOI : 10.1345/aph.1C153
Outcomes from global adult outpatient parenteral antimicrobial therapy programmes: A review of the last decade, International Journal of Antimicrobial Agents, vol.43, issue.1, pp.7-16, 2014. ,
DOI : 10.1016/j.ijantimicag.2013.09.006
Outcomes and Pharmacoeconomic Analysis of a Home Intravenous Antibiotic Infusion Program in Veterans, Clinical Therapeutics, vol.37, issue.11, pp.2527-2562, 2015. ,
DOI : 10.1016/j.clinthera.2015.09.009
The Use of Outpatient Parenteral Antimicrobial Therapy in the Management of Osteomyelitis: Data from the Outpatient Parenteral Antimicrobial Therapy Outcomes Registries, Chemotherapy, vol.47, issue.Suppl. 1, pp.5-16, 2001. ,
DOI : 10.1159/000048563
Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK teaching hospital-based service, Journal of Antimicrobial Chemotherapy, vol.66, issue.2, pp.408-423, 2011. ,
DOI : 10.1093/jac/dkq445
Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme, Journal of Antimicrobial Chemotherapy, vol.64, issue.1, pp.181-188, 2009. ,
DOI : 10.1093/jac/dkp147
Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections, International Journal of Antimicrobial Agents, vol.38, issue.3, pp.243-251, 2011. ,
DOI : 10.1016/j.ijantimicag.2011.05.008
URL : https://hal.archives-ouvertes.fr/hal-00722868
Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis, Journal of Antimicrobial Chemotherapy, vol.68, issue.7, pp.1650-1654 ,
DOI : 10.1093/jac/dkt046
Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis, European Journal of Clinical Microbiology & Infectious Diseases, vol.567, issue.Supplement 2, pp.643-650, 1995. ,
DOI : 10.1007/BF01690746
Le co??t comparatif du traitement par vancomycine versus teicoplanine dans l'infection ost??oarticulaire ?? staphylocoques r??sistants ?? la m??ticilline, Pathologie Biologie, vol.49, issue.7, pp.587-96, 2001. ,
DOI : 10.1016/S0369-8114(01)00203-6
Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy, Journal of Antimicrobial Chemotherapy, vol.51, issue.2, pp.391-397, 2003. ,
DOI : 10.1093/jac/dkg061
Microbiologic Profile of Staphylococci Isolated from Osteoarticular Infections: Evolution over Ten Years, Surgical Infections, vol.16, issue.1, pp.77-83, 2015. ,
DOI : 10.1089/sur.2013.258
Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors, Intensive Care Medicine, vol.29, issue.9, pp.1528-1562, 2003. ,
DOI : 10.1007/s00134-003-1859-z
A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation, Journal of Chronic Diseases, vol.40, issue.5, pp.373-83, 1987. ,
DOI : 10.1016/0021-9681(87)90171-8
Obesity is a Major Risk Factor for Prosthetic Infection after Primary Hip Arthroplasty, Clinical Orthopaedics and Related Research, vol.78, issue.suppl 2, pp.153-161, 2008. ,
DOI : 10.1007/s11999-007-0016-3
Antimicrobial-Related Severe Adverse Events during Treatment of Bone and Joint Infection Due to Methicillin-Susceptible Staphylococcus aureus, Antimicrobial Agents and Chemotherapy, vol.58, issue.2, pp.746-55, 2014. ,
DOI : 10.1128/AAC.02032-13
Bon usage de la Teicoplanine : analyse retrospective d'une pratique clinique dans la prise en charge des infections ostéoarticulaires ,
Sébastien Lustig, Christian Chidiac, et Florent Valour, pour le Lyon BJI study group. Efficacy and tolerance of teicoplanin in Staphylococcus aureus bone and joint infection -Thèse d'exercice ,
Teicoplanin in the treatment of bone and joint infections due to methicillin resistant staphylococci. Experience in adult patients], Medicina (Mex), vol.62, issue.2, pp.40-47, 2002. ,
Morbid Obesity: A Significant Risk Factor for Failure of Two-Stage Revision Total Knee Arthroplasty for Infection, The Journal of Bone and Joint Surgery-American Volume, vol.96, issue.18, p.154, 2014. ,
DOI : 10.2106/JBJS.M.01289
Safety and Efficacy of Teicoplanin for Bone and Joint Infections: Results of a Community-Based Trial, Southern Medical Journal, vol.86, issue.8, 1993. ,
DOI : 10.1097/00007611-199308000-00009
Teicoplanin in the treatment of bone and joint infections: An open study, Journal of Infection and Chemotherapy, vol.5, issue.1, pp.32-41, 1999. ,
DOI : 10.1007/s101560050005
Incidence, characteristics, and outcomes of patients with bone and joint infections due to community-associated methicillin-resistant Staphylococcus aureus: a systematic review, European Journal of Clinical Microbiology & Infectious Diseases, vol.46, issue.6 ,
DOI : 10.1007/s10096-012-1807-3
Risk factors for treatment failure in patients with prosthetic joint infections, Journal of Hospital Infection, vol.75, issue.4, 2010. ,
DOI : 10.1016/j.jhin.2010.03.012
Outcome of prosthetic joint infections treated with debridement and retention of components. Clin Infect Dis Off Publ Infect Dis Soc Am, Feb, vol.1542, issue.4, pp.471-479, 2006. ,
Clinical characteristics and therapeutic outcomes of hematogenous vertebral osteomyelitis caused by methicillin-resistant Staphylococcus aureus, Journal of Infection, vol.67, issue.6, pp.556-64, 2013. ,
DOI : 10.1016/j.jinf.2013.07.026
Results of Periprosthetic Hip and Knee Infections Caused by Resistant Bacteria, Clinical Orthopaedics and Related Research, vol.404, issue.404, pp.116-140, 2002. ,
DOI : 10.1097/00003086-200211000-00021
Higher Risk of Failure of Methicillin-resistant Staphylococcus aureus Prosthetic Joint Infections, Clinical Orthopaedics and Related Research, vol.PAP, pp.48-53, 2007. ,
DOI : 10.1097/BLO.0b013e3181123d4e
Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy, The American Journal of Medicine, vol.114, issue.9, pp.723-731, 2003. ,
DOI : 10.1016/S0002-9343(03)00231-6
Drug Sensitivity and Teicoplanin Resistance of Coagulase-negative Staphylococcus Isolated from Blood Culture, Journal of the Japanese Association for Infectious Diseases, vol.78, issue.1, pp.46-53, 2004. ,
DOI : 10.11150/kansenshogakuzasshi1970.78.46
Relationship of teicoplanin MICs to treatment failure in teicoplanin-treated patients with methicillin- 110 ,
The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis, Clinical Infectious Diseases, vol.54, issue.6, 2012. ,
DOI : 10.1093/cid/cir935
Tolérance locale de la téicoplanine après administration prolongée en sous-cutanée chez 27 patients traités pour des infections ostéoarticulaires, p.2015 ,
Coignard pour le groupe ,
Prolonged subcutaneous high dose (1??g bid) of Ertapenem as salvage therapy in patients with difficult-to-treat bone and joint infection, Journal of Infection, vol.65, issue.6, pp.579-82, 2012. ,
DOI : 10.1016/j.jinf.2012.09.004
URL : https://hal.archives-ouvertes.fr/inserm-00734708
Skin necrosis following administration of subcutaneous gentamicin]. Presse Médicale Paris Fr 1983, Jun, vol.1613, issue.25, pp.1575-1581, 1984. ,
Pharmacokinetics and tolerance of ceftriaxone after subcutaneous administration], Pathol Biol, vol.36, issue.5 2, pp.702-707, 1988. ,
Long-term, once-weekly outpatient teicoplanin use for suppression of chronic prosthetic joint infection, International Journal of Antimicrobial Agents, vol.41, issue.2, pp.200-201, 2013. ,
DOI : 10.1016/j.ijantimicag.2012.10.006
guillon@univ-tours.fr)1,2,3, Sabine Baron3, Sharmeen Gettner3, 2008. ,
Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil, Clinical Microbiology and Infection, vol.14, issue.2, pp.116-139, 2008. ,
DOI : 10.1111/j.1469-0691.2007.01885.x